Citations (18)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (1)
Sylvi Irawati, Johanna E. Emmens, Stijn de Vos, Jens H. J. Bos, Rudolf A. de Boer & Eelko Hak. (2022) Association between adherence to statin therapy and low-density lipoprotein cholesterol (LDL-c) response in first-time users of standard-dose and low-dose statins: the PharmLines initiative. Current Medical Research and Opinion 38:1, pages 1-6.
Read now
Read now
Articles from other publishers (17)
Dennis Steenhuis, Xuechun Li, Talitha Feenstra, Eelko Hak & Stijn de Vos. (2023) The Association between Deductibles and Cardiovascular Medication Adherence: A Retrospective Inception Cohort Study. Drugs - Real World Outcomes 11:1, pages 99-108.
Crossref
Crossref
Ammar Abdulrahman Jairoun, Chong Chee Ping & Baharudin Ibrahim. (2023) The crucial role of community pharmacists in balancing the impact of statins on kidney function in patients with diabetes mellitus: Recommendations for awareness, recognition, and management of diabetic nephropathy. Obesity Medicine 42, pages 100506.
Crossref
Crossref
Martin Wawruch, Miriam Petrova, Tomas Tesar, Jan Murin, Patricia Schnorrerova, Martina Paduchova, Denisa Celovska, Beata Havelkova, Michal Trnka, Sofa D. Alfian & Emma Aarnio. (2023) Factors associated with non-adherence to angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in older patients with peripheral arterial disease. Frontiers in Pharmacology 14.
Crossref
Crossref
Dennis Steenhuis, Stijn de Vos, Jens H.J. Bos & Eelko Hak. (2023) Risk factors for drug-treated major adverse cardio-cerebrovascular events in patients on primary preventive statin therapy: A retrospective cohort study. Preventive Medicine Reports 34, pages 102258.
Crossref
Crossref
Dennis Steenhuis, Stijn de Vos, Jens Bos & Eelko Hak. (2022) Role of Traditional Cardiovascular Risk Factors after Initiation of Statin Therapy: A PharmLines Inception Cohort Study. Cardiovascular Therapeutics 2022, pages 1-9.
Crossref
Crossref
Qais Alefan, Shenzhen Yao, Jeffrey G. Taylor, Lisa M. Lix, Dean Eurich, Niteesh Choudhry & David F. Blackburn. (2022) Factors associated with early nonpersistence among patients experiencing side effects from a new medication. Journal of the American Pharmacists Association 62:3, pages 717-726.e5.
Crossref
Crossref
Kyu Hyung Park, Leonie Tickle & Henry Cutler. (2022) Identifying temporal patterns of adherence to antidepressants, bisphosphonates and statins, and associated patient factors. SSM - Population Health 17, pages 100973.
Crossref
Crossref
Christel Hero, Sofia Axia Karlsson, Stefan Franzén, Ann-Marie Svensson, Mervete Miftaraj, Soffia Gudbjörnsdottír, Karolina Andersson-Sundell, Björn Eliasson & Katarina Eeg-Olofsson. (2021) Impact of Socioeconomic Factors and Gender on Refill Adherence and Persistence to Lipid-Lowering Therapy in Type 1 Diabetes. Diabetes Therapy 12:9, pages 2371-2386.
Crossref
Crossref
Martin Wawruch, Gejza WimmerJr.Jr., Jan Murin, Martina Paduchova, Miriam Petrova, Tomas Tesar, Petra Matalova, Beata Havelkova, Michal Trnka & Emma Aarnio. (2020) Non-Adherence to Statin Treatment in Older Patients with Peripheral Arterial Disease Depending on Persistence Status. Biomedicines 8:10, pages 378.
Crossref
Crossref
Muh. Akbar Bahar, Jens H. J. Bos, Sander D. Borgsteede, Aafje Dotinga, Rolinde A. Alingh, Bob Wilffert & Eelko Hak. (2020) Prevalence and Accuracy of Information on CYP2D6, CYP2C19, and CYP2C9 Related Substrate and Inhibitor Co-Prescriptions in the General Population: A Cross‐Sectional Descriptive Study as Part of the PharmLines Initiative. Frontiers in Pharmacology 11.
Crossref
Crossref
Feiyu Hu, Jim Warren & Daniel J. Exeter. (2020) Predicting Lipid-Lowering Medication Persistence after the First Cardiovascular Disease Hospitalization. Methods of Information in Medicine 59:02/03, pages 061-074.
Crossref
Crossref
Sofa D. Alfian, Petra Denig, André Coelho & Eelko Hak. (2019) Pharmacy-based predictors of non-adherence, non-persistence and reinitiation of antihypertensive drugs among patients on oral diabetes drugs in the Netherlands. PLOS ONE 14:11, pages e0225390.
Crossref
Crossref
Björn Wettermark, Vera Vlahović‐Palčevski, David Lee & Ulf Bergman. 2019. Pharmacoepidemiology. Pharmacoepidemiology
373
410
.
Martin Wawruch, Gejza WimmerJrJr, Jan Murin, Martina Paduchova, Tomas Tesar, Lubica Hlinkova, Peter Slavkovsky, Lubomira Fabryova & Emma Aarnio. (2019) Patient-Associated Characteristics Influencing the Risk for Non-Persistence with Statins in Older Patients with Peripheral Arterial Disease. Drugs & Aging 36:9, pages 863-873.
Crossref
Crossref
Cesar I. Fernandez-Lazaro, David P. Adams, Diego Fernandez-Lazaro, Juan M. Garcia-González, Alberto Caballero-Garcia & Jose A. Miron-Canelo. (2019) Medication adherence and barriers among low-income, uninsured patients with multiple chronic conditions. Research in Social and Administrative Pharmacy 15:6, pages 744-753.
Crossref
Crossref
Michael L. Dansinger, Paul T. Williams, H. Robert Superko & Ernst J. Schaefer. (2019) The importance of cholesterol follow-up testing under current statin treatment guidelines. Preventive Medicine 121, pages 150-157.
Crossref
Crossref
Muh. Akbar Bahar, Yuanyuan Wang, Jens H.J. Bos, Bob Wilffert & Eelko Hak. (2018) Discontinuation and dose adjustment of metoprolol after metoprolol‐paroxetine/fluoxetine co‐prescription in Dutch elderly. Pharmacoepidemiology and Drug Safety 27:6, pages 621-629.
Crossref
Crossref